[Featured Stock] Hyundai Bio Proves Oral Anticancer Drug Effectiveness...Solves 60-Year-Old Unresolved Problem

Hyundai Bio is showing strong performance. The news that the 'niclosamide-based oral metabolic anticancer drug,' developed jointly with C&Pharm, demonstrated 67% greater anticancer efficacy when co-administered with the chemical anticancer drug docetaxel appears to be influencing the stock price. The preclinical results are planned to be published through an SCI-level paper.

As of 9:27 AM on the 19th, Hyundai Bio is trading at 20,750 KRW, up 3.23% from the previous day.

Hyundai Bio announced that it has succeeded in drug repositioning niclosamide, which has been found effective in treating various cancers by acting on the metabolic processes of cancer cells through decades of cell experiments, into an oral metabolic anticancer drug.

Metabolic anticancer drugs disrupt the unique metabolic mechanisms of cancer cells and block neurotransmitter systems to inhibit the growth and survival of cancer cells. When co-administered with existing anticancer drugs, the anticancer effect is further enhanced.

Niclosamide disrupts cancer cell metabolism, inhibiting proliferation and survival, and blocks major neurotransmitter systems in cancer cells to prevent the development of resistance to anticancer drugs, according to cell experiment results. It is a representative metabolic anticancer substance that suppresses cancer stem cells and prevents cancer recurrence and metastasis. It is known that only niclosamide anticancer drugs can simultaneously solve the problems of resistance and metastasis.

Due to this anticancer mechanism, niclosamide is effective against various cancers such as lung cancer, breast cancer, prostate cancer, colorectal cancer, liver cancer, kidney cancer, and head and neck cancer. It is especially known to be highly effective against intractable cancers that show resistance to existing anticancer treatments, including triple-negative breast cancer, lung cancer, prostate cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and head and neck cancer.

Although niclosamide has been found to have excellent anticancer effects, it has not reached clinical trials in humans for over 60 years due to unresolved issues of 'low absorption rate' and 'short maintenance time of effective drug concentration in the blood.'

Hyundai Bio, in collaboration with C&Pharm, announced that they have completed an oral anticancer drug formulation with a drug concentration (IC50) that suppresses cancer cell proliferation within a niclosamide dose that does not cause toxicity, using their patented 'drug delivery system technology.'

Jin Geun-woo, head of research at Hyundai Bio, commented on the significance of the preclinical results, saying, "This is the first case to statistically prove in vivo that oral niclosamide anticancer drugs have excellent effects on the intractable cancer triple-negative breast cancer," and added, "Niclosamide metabolic anticancer drugs can solve the problems of resistance and metastasis that make anticancer treatment impossible." He further stated, "We plan to conduct clinical phase 1/2a trials in Korea targeting several intractable cancers, including triple-negative breast cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and metastatic prostate cancer."